Comparison of Intravenous plus Oral Pantoprazole Therapy and Oral Pantoprazole Alone for Preventing Gastrointestinal Bleeding in Acute Coronary Syndrome Patients with High Bleeding Risk

Heart Lung and Circulation

Volumn 24, Issue 9, 2015, Pages 885-890

  Yao, Dao Kuo ^a   Chen, Hui ^a   Wang, Lei ^a   Li, Hong Wei ^a   Wang, Le Xin ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CHARLES STURT UNIVERSITY   (Australia)

Author keywords

Acute coronary syndrome; Gastrointestinal bleeding; Major adverse cardiac events; Mortality; Pantoprazole

Indexed keywords

PANTOPRAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART DEATH; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME; COMPARATIVE STUDY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ACUTE CORONARY SYNDROME; ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; AGED; GASTROINTESTINAL HEMORRHAGE; HUMANS; MIDDLE AGED; RISK FACTORS;

EID: 84940797004     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2015.02.020     Document Type: Article

References (28)

1. Chua S.K., Liao C.S., Hung H.F., Cheng J.J., Chiu C.Z., Chang C.M., et al. Gastrointestinal bleeding and outcomes after percutaneous coronary intervention for ST-segment elevation myocardial infarction. Am J Crit Care 2011, 20:218-225.
2. Ng F.H., Lam K.F., Wong S.Y., Chang C.M., Lau Y.K., Yuen W.C., et al. Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy. Digestion 2008, 77:173-177.
3. Sabatine M.S., Cannon C.P., Gibson C.M., Lopez-Sendon J.L., Montalescot G., Theroux P., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005, 352:1179-1189.
4. Moukarbel G.V., Signorovitch J.E., Pfeffer M.A., McMurray J.J., White H.D., Maggioni A.P., et al. Gastrointestinal bleeding in high risk survivors of myocardial infarction: The VALIANT trial. Eur Heart J. 2009, 30:2226-2232.
5. Abbas A.E., Brodie B., Dixon S., Marsalese D., Brewington S., O'Neill W.W., et al. Incidence and prognostic impact of gastrointestinal bleeding after percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol. 2005, 96:173-176.
6. Bhatt D.L., Cryer B.L., Contant C.F., Cohen M., Lanas A., Schnitzer T.J., et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010, 363:1909-1917.
7. Abraham N.S., Hlatky M.A., Antman E.M., Bhatt D.L., Bjorkman D.J., Clark C.B., et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 2010, 122:2619-2633.
8. Ray W.A., Murray K.T., Griffin M.R., Chung C.P., Smalley W.E., Hall K., et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: A cohort study. Ann Intern Med. 2010, 152:337-345.
9. Baker D.E. Intravenous proton pump inhibitors. Rev Gastroenterol Disord. 2006, 6:22-34.
10. Barkun A.N., Bardou M., Kuipers E.J., Sung J., Hunt R.H., Martel M., et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010, 152(2):101-113.
11. Sung J.J., Chan F.K., Chen M., Ching J.Y., Ho K.Y., Kachintorn U., et al. Asia-Pacific Working Group consensus on non-variceal upper gastrointestinal bleeding. Gut 2011, 60(9):1170-1177.
12. Yen H.H., Yang C.W., Su W.W., Soon M.S., Wu S.S., Lin H.J. Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy. BMC Gastroenterol 2012, 12:66.
13. Nikolsky E., Mehran R., Dangas G., Fahy M., Na Y., Pocock S.J., et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J. 2007, 28:1936-1945.
14. Sung J.J., Lau J.Y., Ching J.Y., Wu J.C., Lee Y.T., Chiu P.W., et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: A randomized trial. Ann Intern Med. 2010, 152:1-9.
15. Silvain J., Pena A., Cayla G., Brieger D., Bellemain-Appaix A., Chastre T.V., et al. Impact of red blood cell transfusion on platelet activation and aggregation in healthy volunteers: Results of the transfusion study. Eur Heart J. 2010, 31:2816-2821.
16. Steg P.G., Huber K., Andreotti F., Arnesen H., Atar D., Badimon L., et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: Position paper by the working group on thrombosis of the european society of cardiology. Eur Heart J 2011, 32:1854-1864.
17. Fontes-Carvalho R., Albuquerque A., Araujo C., Pimentel-Nunes P., Ribeiro V.G. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: A randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-ppis drug interaction. Eur J Gastroenterol Hepatol. 2011, 23:396-404.
18. Munoz-Torrero J.F., Escudero D., Suarez C., Sanclemente C., Pascual M.T., Zamorano J., et al. Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the Factores de Riesgo y Enfermedad Arterial (FRENA) Registry. J Cardiovasc Pharmacol. 2011, 57:13-19.
19. Gerson L.B. Proton pump inhibitors and potential interactions with clopidogrel: An update. Curr Gastroenterol Rep. 2013, 15:329.
20. Tsantes A.E., Ikonomidis I., Papadakis I., Bonovas S., Gialeraki A., Kottaridi C., et al. Impact of the proton pump inhibitors and cyp2c192 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays. Thromb Res. 2013, 132:e105-e111. http://www.ncbi.nlm.nih.gov/pubmed/23830212 (Last Accessed: February 26, 2014).
21. Bacaksiz A., Teker M.E., Buyukpinarbasili N., Inan O., Tasal A., Sonmez O., et al. Does pantoprazole protect against reperfusion injury following myocardial ischemia in rats?. Eur Rev Med Pharmacol Sci. 2013, 17:269-275.
22. Goodman S.G., Clare R., Pieper K.S., Nicolau J.C., Storey R.F., Cantor W.J., et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: Insights from the platelet inhibition and patient outcomes trial. Circulation. 2012, 125:978-986.
23. Bhurke S.M., Martin B.C., Li C., Franks A.M., Bursac Z., Said Q. Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome. Pharmacotherapy 2012, 32:809-818.
24. Stockl K.M., Le L., Zakharyan A., Harada A.S., Solow B.K., Addiego J.E., et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med. 2010, 170:704-710.
25. Sarafoff N., Sibbing D., Sonntag U., Ellert J., Schulz S., Byrne R.A., et al. Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors. Thromb Haemost. 2010, 104:626-632.
26. Juurlink D.N., Dormuth C.R., Huang A., Hellings C., Paterson J.M., Raymond C., et al. Proton pump inhibitors and the risk of adverse cardiac events. PLoS One. 2013, 8:e84890. http://www.ncbi.nlm.nih.gov/pubmed/24386430 (Last Accessed: February 26, 2014).
27. Garcia Rodriguez L.A., Johansson S., Nagy P., Cea Soriano L. Use of proton pump inhibitors and the risk of coronary events in new users of low-dose acetylsalicylic acid in uk primary care. Thromb Haemost 2014, 111:131-139.
28. Douglas I.J., Evans S.J., Hingorani A.D., Grosso A.M., Timmis A., Hemingway H., et al. Clopidogrel and interaction with proton pump inhibitors: Comparison between cohort and within person study designs. BMJ. 2012, 345:e4388. http://www.ncbi.nlm.nih.gov/pubmed/22782731 (Last Accessed: February 26, 2014).